SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : lcav

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Larry Williams who wrote (814)5/27/1999 12:22:00 AM
From: W Shakespeare  Read Replies (2) of 942
 
I would not be too happy about today's news about VISX. You have perhaps noticed that all the major players in the industry dropped on the news. Here is why (from the latest S-3/A of LVCI):

"SIGNIFICANT DECREASES IN EXCIMER LASER PRICES COULD HARM OUR BUSINESS BY MAKING
IT MORE ATTRACTIVE
FOR EYE SURGEONS TO BUY THEIR OWN LASERS AND BY FORCING US TO LOWER PRICES
A significant reduction in the price of excimer lasers could reduce demand
for our services by making it economically more attractive for eye surgeons to
buy excimer lasers for themselves instead of paying us a per procedure fee.
Also, excimer laser price decreases could force us to reduce our fees in
response to this reduction in demand or as a means to remain competitive with
other laser access providers. The excimer lasers we use currently have a retail
price of $525,000."

If VISX loses its patent protection, then we will have lots of companies making low priced lasers. Eye doctors will buy the lasers outright and bypass companies like LCAV, LVCI, and OHSI. The industry will be crushed as will your and my investments. Eye surgery will be inexpensive and totally unprofitable from an investment prospective.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext